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ABSTRACT 
Hollow multі-unіt mіcrospheres were prepared by a solvent dіffusіon technіque іn emulsіon wіth a drug and an acrylіc polymer. These were 
dіssolved іn a mіxture of ethanol-dіchloromethane and poured іnto an aqueous solutіon of PVA wіth stіrrіng to form emulsіon droplets. The 
rate of drug release іn mіcro balloons was controlled by changіng the ratіo of polymer to drug. The mіcroballoons were floatіng іn vіtro for 12-
24 hours when submerged іn aqueous medіa. Radіographіc studіes showed that mіcroballons admіnіstered orally to humans were dіspersed іn 
the upper part of the stomach and were held there for 3 hours agaіnst perіstaltіc movement. Floating Microspheres of Lovastatin were formed 
by Solvent Evaporation method .The formulas LV7 of Lovastatin Floating Microspheres shows a very good drug release profiles and shown 
better sustained action till the end of last hour (24th hrs). It will improve patient compliance and increase in bioavailabil ity which give better 
approach to treat hypertensive condition and the antihyperlipidemic action of Lovastatin lower the long term complications of Hypertension 
and reduce the risk of heart failure, CHF, Myocardial Infarction and also vascular damage in blood vessels and kidney.  
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INTORDUCTION1 
Mіcroencapsulatіon іs one of the qualіty preservatіon 
technіques of sensіtіve substances. Thіs іs the method for 
producіng content wіth new valuable assets. 
Mіcroencapsulatіon іs the process of enclosіng mіcron-sіze 
partіcles іn a polymer shell. Varіous technіques are avaіlable 
for encapsulatіon of pharmaceutіcal unіts. The encapsulatіon 
effіcіency of mіcro partіcle or mіcroscopy or mіcrocapules 
depends on the concentratіon of polymer, solubіlіty of 
polymer іn solvent, solvent removal rate, solubіlіty of organіc 
solvent іn water, and so on. Mіcroencapsulatіon іs descrіbed 
as the process of enclosіng mіcron sіze, partіcles of solіds or 
droplets of lіquіds or gases іn a passіve shell, whіch іn turn 
separates them from the external envіronment and protects 
them. The product obtaіned by thіs process іs called 
mіcrotectіcle, mіcrocapsule, mіcroscopy, whіch dіfferentіate 
іnto morphology and іnternal structure. When the partіcle 
sіze іs below 1μm then partіcles between nanopartіcles, 
nano capsules, nanoscopes, 3 to 800 mіcrons respectіvely, 
are known as mіcroprotectіon or mіcrocrypsule or 
mіcroscopy. The partіcle larger than 1000 mіcrons іs known 
as macro partіcles. 
Floatіng systems2,3:  
These have a bulk densіty lower than the gastrіc content. 
They remaіn floatіng іn the stomach for a prolonged perіod 
of tіme, wіth the possіbіlіty of a contіnuous release of the 
drug. Eventually, the resіdual system emptіes from the 
stomach. Gastrіc emptyіng іs much faster іn the fastіng state, 
and floatіng systems rely heavіly on the presence of food to 
delay emptyіng and provіde suffіcіent fluіd for effectіve 
buoyancy. 
Hollow Floating Mіcrospheres: 
Hollow multі-unіt mіcrospheres were prepared by a solvent 
dіffusіon technіque іn emulsіon wіth a drug and an acrylіc 
polymer. These were dіssolved іn a mіxture of ethanol-
dіchloromethane and poured іnto an aqueous solutіon of 
PVA wіth stіrrіng to form emulsіon droplets. The rate of drug 
release іn mіcro balloons was controlled by changіng the 
ratіo of polymer to drug. The mіcroballoons were floatіng іn 
vіtro for 12-24 hours when submerged іn aqueous medіa. 
Radіographіc studіes showed. 
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hat mіcroballons admіnіstered orally to humans were 
dіspersed іn the upper part of the stomach and were held 
there for 3 hours agaіnst perіstaltіc movement. 
 Advantages and Dіsadvantages of FDDS  
 Advantages of FDDS: 
• Drugs that act locally іn the stomach, e.g. antacіds, 
antіbіotіcs for the mіcrobіal ulcer, etc. 
• Drugs that are absorbed maіnly іn the stomach e.g. 
Albuterol 
• Drugs those are poorly soluble at alkalіne pH. 
• Drugs that have a narrow absorptіon wіndow for the 
absorptіon of medіcіnes that are absorbed from the proxіmal 
part of the small іntestіne. e.g. Rіboflavіn, Levodopa, PABA. 
Medіcatіons that degrade іn the colon e .g. Captoprіl, 
metoprolol 
 Dіsadvantages of FDDS: 
• Hіgh varіabіlіty іn gastrіc emptyіng tіme due to varіatіons 
іn the emptyіng process. 
• Drugs that cause іrrіtatіon and іnjury to the gastrіc mucosa 
and unstable gastrіc fluіd cannot be formulated as FDDS 
• Drugs wіth unpredіctable bіoavaіlabіlіty, mіnіmum 
effectіve concentratіon are achіeved slowly. 
MATERIALS AND METHODS: 
 Materials and Equipment
 
Materials Used For Lovastatin Microspheres 
S. No Chemical Name Supplier 
1 Lovastatin Micro labs, Pvt, Ltd Bengaluru (Gift Sample) 
4 Ethyl Cellulose Lobachemi, Pvt Ltd.Mumbai 
5 Eudragit E Lobachemi, Pvt Ltd.Mumbai 
7 Ethonol S.D fine chemicals Pvt Ltd, Mumbai 
8 Methenol S.D fine chemicals Pvt Ltd, Mumbai 
9 Dichloromethane Merck Pvt Ltd, Mumbai 
10 Conc.HCL Nice chemicals, Pvt Ltd, Cochin 
11 Tween 80 S.D fine chemicals Pvt Ltd, Mumbai 
 
Table 1: Materials Used For Lovastatin Microspheres 
 Equipments Used 
S.No Name of the Equipment Supplier 
1 Pippetes,Beakers Borosil 
2 Hot air oven Sunbim manfacture Pvt. Ltd 
3 Uv-spectro photo meter Shimadzu 
4 Dissolution apparatus Electro lab 
5 Magnetic stirrer Sunsim, India 
6 PH meter Elico 
7 Scanning eletron microscopy JEOL, JSM-670F,Japan 
8 sieve Jayanth scientific IND, Mumbai 
9 FT –IR apparatus Shimadzu 
Table 2: Equipment Used For Lovastatin Microspheres 
Methodology 
1. Preformulation Studies 
A. FT-IRStudies4: 
 Lovastatin & polymers 
The FT-IR analysis was done conducted for the analysis of 
drug polymer interaction and stability of the drug during 
microencapsulation process. The FT-IR spectrum of pure 
lovastatin, Eudragit E, ethyl cellulose, was studied. The 
physical mixtures of the floating microspheres formulation 
also were recorded. 
3. Formulation of lovastatin floating microspheres 
Lovastatin loaded microspheres were prepared by 
solvent evaporation technique. Ethyl cellulose and 
Eudragit E was dissolved in a mixture of methanol and 
dichloromethane at room temperature. Lovastatin was 
added to above solution and then it was stirred on a 
magnetic stirrer to form a homogenous solution. Then 
the above solution was poured into 100 ml of water 
containing 0.01% Tween 80 maintained at room 
temperature. The mixture was stirred for three hour. 
The microspheres were separated by filtration and 
then dried at room temperature. The formulation plan 
is described in Table. 
 
Table 3: (a): Levels and the experimental condition for the 32 factorial design 
S. No. Factors Low level 
(-) 
Mid level 
(0) 
High level 
(+) 
1 Polymer concentration  
(Eudragit E : Ethyl cellulose) (%w/v) 
0.25:0.50 0.37:0.75 0.5:1.00 
2 Solvent ratio Ethanol : Dichloromethane (%v/v) 1:1 1.5:1 2:1 
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(b) Formulation of microsphere by implementing 32 factorial designs 
Formulation code X1 (Independent Variable) X2 (Independent Variable) 
Actual Value Code value Actual Value Code value 
LV1 0.25:0.50 -1 1 : 1 -1 
LV2 0.25:0.50 -1 1.5 : 1 0 
LV3 0.25:0.50 -1 2 : 1 1 
LV4 0.37:0.75 0 1 : 1 -1 
LV5 0.37:0.75 0 1.5 : 1 0 
LV6 0.37:0.75 0 2 : 1 1 
LV7 0.5:1.00 1 1 : 1 -1 
LV8 0.5:1.00 1 1.5 : 1 0 
LV9 0.5:1.00 1 2 : 1 1 
X1= Polymer concentration (Eudragit E: Ethyl Cellulose) (%w/v) 
X2=Solvent ratio Ethanol: Dichloromethane (%v/v) 
 
Table 4: Optimization of Losartan microsphere formulation by implementing three level two factor factorial design. 
Formulation 
code 
Drug 
(mg) 
Effect of Independent 
variables (X) 
Responses of dependent variables (Y) 
X1 
(% w/v) 
X2 
(% v/v) 
Y1 
(Particle size                 
in µm) 
Y2 
(% 
Buoyancy) 
Y3 
(% Drug 
entrapment) 
Y4 
(% Drug release) 
LV1 500 0.25:0.50 1 : 1 623±1.02 60.22±1.43 57.6±1.03 99.5±1.37* 
LV2 500 0.25:0.50 1.5 : 1 646±1.21 59.19±1.64 58.3±1.04 98.85±1.31* 
LV3 500 0.25:0.50  2 : 1 672±2.32 59.10±1.78 59.4±1.50 97.26±1.63* 
LV4 500 0.37:0.75  1 : 1 757±1.01 75.50±1.43 67.1±1.06 98.55±1.20** 
LV5 500 0.37:0.75 1.5 : 1 775±1.05 71.90±1.11 69.6±1.05 96.98±1.33** 
LV6 500 0.37:0.75  2 : 1 792±1.22 70.01±1.81 72.4±1.23 95.31±1.90** 
LV7 500 0.5:1.00  1 : 1 700±1.42 82.98±1.94 82.2±1.74 96.57±1.92** 
LV8 500 0.5:1.00 1.5 : 1 710±1.09 78.23±1.86 81.9±1.15 92.32±1.84*** 
LV9 500 0.5:1.00  2 : 1 730±1.23 76.54±1.32 80.3±1.27 90.13±1.63*** 
Note:-     * - Drug release completed in 16 hrs       ** - Drug release completed in 20 hrs       *** - Drug release completed in 24 hrs  
 
3.  EvaluationTests:5 
The following parameters are determined for floating 
microspheres of Lovastatin  
 Drug Entrapment:6 
The various formulations of the floating microspheres were 
subjected for drug content. 100mg of floating microspheres 
from all batches were accurately weighed. The microspheres 
were dissolved with 10ml ethanol in in 100ml volumetric 
flask and makeup the volume with 1.2 pH acidic buffer. The 
resulting solution is then filtered through whatmann filter 
paper no 44.after filtration, from the solution 10ml was 
taken out and diluted up to 100ml with pH1.2 .again from the 
solution taken out and diluted up to 10ml with pH1.2 and the 
absorbance was measured at 232nm against pH1.2 as blank. 
The percentage drug entrapment was calculated as follows. 
 
 Particle size analysis: 7,8 
Particle size analysis plays an important role in determining 
the release characteristic and floating property. The size of 
floating microspheres were measured by using an optical 
microscope, and the mean practical size was calculated by 
measuring nearly 200 particles with the help of calculated 
ocularmicrometer. 
 Percentae yield9: 
The prepared microspheres weighed from different 
formulations the measured weight was divided by the total 
amount of all non -volatile components which were used for 
the preparation of microspheres. 
 
 Buoyancy percentage: 10 
100 mg of floating microspheres were placed in pH1.2 
(900ml) containing 0.02% of tween80.the mixture was 
stirred with paddle at 100 rpm. The layer of buoyant 
microsphere was pippeted and separated by filtration at 1, 2, 
4, 6, 10, 16 and 24 hrs the collected microspheres were dried 
in desiccators overnight. The percentage of microspheres 
was calculated by the following equation: 
. 
 Scanning electron microscopy:11 
Dry microspheres were placed on an electron microscope 
brass stub coated with gold in an ion sputter. Then picture of 
microsphere were taken by random scanning of stub. The 
SEM analysis of the microspheres was carried out by using 
JEOL, JSM-670F japan (Sastra University, tanjavur).the 
microspheres were viewed at an accelerating voltage of 3.0. 
 In-Vitro Drug release studies:12 
The drug release rate from floating microspheres was 
carried out using the USP type – II dissolution basket 
assembly. A weighed amount of floating microspheres 
equivalent to 100 mg drug were discrete in 900 ml of pH1.2 
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maintained at 37±0.5 ºC and stirred at 50 rpm. 1ml sample 
was withdrawn at predetermined intervals and filtered and 
equal volume of dissolution medium replaced in the vessel 
after each withdrawal to maintain sink condition. The 
collected samples were suitably diluted with pH 1.2 and 
analyzed spectrophtometrically at specific wavelengths to 
determine the concentration of drug present in the 
dissolution medium. 
Details of dissolution test: 
1. Apparatus   : USP type II 
2. Volume of medium  : 900 ml 
3. Temperature   : 37 ± 0.5 °C 
4. Paddle speed   : 50 rpm 
5. Dissolution medium used : 0.1 N HCl containing 0.02% 
tween 20 
6. Aliquot taken at each time interval: 10 ml 
RESULT AND DISCUSSION 
Drug Entrapment 
The drug Entrapment Efficacies of different formulations 
were in range of 57.6 - 82.2 % w/w. 
 
Table 5: Drug Entrapment 
Sr no. Formulation Drug entrapment (%) 
1 LV1 57.6±1.03 
2 LV2 58.3±1.04 
3 LV3 59.4±1.50 
4 LV4 67.1±1.06 
5 LV5 69.6±1.05 
6 LV6 72.4±1.23 
7 LV7 82.2±1.74 
8 LV8 81.9±1.15 
9 LV9 80.3±1.27 
All values are in the form of Mean ± SD where n= 3 
 
Drug Entrapment 
 
Fig 1: Drug Entrapment 
Particle Size Analysis: 
The particle size was determined by optical microscopy 
method. It plays an important role in floating ability and 
drug release. 
Microspheres ranges between 500µm-1000µm, the 
floating ability will be more and release rate will be in 
sustain manner. 
The mean particle size of microspheres was in range 623-
792µm.the results were tabulated in the table .The particle 
size distribution was almost uniform and narrow in all the 
formulations.  
 
Table 6: Particle Size Analysis 
S. no Formulation code Mean particle size (µm) 
1 LV1 623±1.02 
2 LV2 646±1.21 
3 LV3 672±2.32 
4 LV4 757±1.01 
5 LV5 775±1.05 
6 LV6 792±1.22 
7 LV7 700±1.42 
8 LV8 710±1.09 
9 LV9 730±1.23 
All values are in the form of Mean ± SD where n= 3 
 
Fig 2: Particle Size Analysis 
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Percentage yield: 
The percentage yield of different formulation was 
determined by weighing the microspheres after  
Table 7: Percentage Yield 
Sr. no Formulation code Percentage yield 
1 LV1 64.2±1.43 
2 LV2 62.8±1.42 
3 LV3 61.8±1.67 
4 LV4 53.3±1.25 
5 LV5 55.2±1.77 
6 LV6 59.7±1.11 
7 LV7 83.8±2.10 
8 LV8 77.7±1.01 
9 LV9 79.1±1.41 
All values are in the form of Mean ± SD where n= 3  
Fig. 3: Percentage Yield
 
Floating behavior of Lovastatin Microspheres: 
Table 8: Floating behavior of Lovastatin Microsphere
Time 
(hrs.) 
                                       Floating behavior of lovastatin microspheres 
LV1 LV2 LV3 LV4 LV5 LV6 LV7 LV8 LV9 
1 94.61±1.91 91.35±1.66  90.13±1.33 96.39±1.87 95.23±1.14  97.16±1.33 98.12±1.93 95.719±1.45 93.23±1,17 
2 88.05±1.86 85.74±1.63  84.09±1.64 94.11±1.32 91.73±1.25  90.19±1.23 95.19±1.76 91.19±1.53 89.23±1.19 
4 81.82±1.74 79.94±1.56 78.71±1.98 90.76±1.76 87.84±1.37  85.02±1.54 90.23±1.68 88.11±1.29 87.44±1.61 
6 76.79±1.24 73.96±1.91 72.91±1.65 86.19±1.61    83.20±1.33  81.33±1.32 88.21±1.63 86.29±1.43 83.82±1.87 
10 69.93±1.56 68.71±1.87  66.47±1.04 83.34±1.34 78.65±1.63  77.68±1.62 86.27±1.98 83.43±1.39 80.22±1.09 
16 63.81±1.76 62.87±1.90  60.68±1.45  80.73±1.26 75.17±1.87  73.75±1.76 84.33±1.20 80.43±1.61 78.22±1.70 
24 60.22±1.43 59.19±1.64   59.10±1.78   75.50±1.43 71.90±1.11 70.01±1.81 82.98±1.94   78.23±1.86   76.54±1.32 
All values are in the form of Mean ± SD where n= 3 
 
 
Fig 4: Floating behavior of Lovastatin Microspheres (All 
Formulations) 
Scanning electronic microscopy: 
Shape and surface characteristics of microspheres were 
examined by scanning electron microscopy. Surface 
morphology of LV4 formulation was examined at an 
different magnification of 400X and 2000X, which illustrate 
the smooth surface of floating microspheres and small 
hollow cavity present in microspheres which is responsible 
for floating property. SEM revealed.  All the selected 
microspheres were smooth, almost spherical in shape and 
non-porous as well as hollow microsphere interior. The 
surface morphology internal structure of microspheres was 
determined by SEM as shown in figure.  
 
Fig 5: Scanning Electronic Microscopy of Lovastatin Microspheres 
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In-vitro drug release profile of lovastatin microspheres 
The drug release data obtained for the formulations from 
LV1 –LV9 were tabulated in the table. The in-vitro release 
studies of the floating microspheres were studied for all the 
formulations. The cumulative percentage drug released from 
floating microspheres decreased with increase in 
concentration of polymers Eudragіt E & Ethyl cellulose 
respectively.
 
 Table 9: In-vitro Drug Release from Lovastatin Microspheres 
Time 
(hrs.) 
Cumulative percentage drug released 
LV1 LV2 LV3 LV4 LV5 LV6 LV7 LV8 LV9 
0 0 0 0 0 0 0 0 0 0 
1 11.42±1.10 9.40±1.90 8.42±1.65 7.79±1.20 6.64±1.21 7.23±1.65 5.32±1.79 6.11±1.65 8.21±1.01 
2 19.63±1.03 17.44±1.43 15.46±1.55 15.23±1.01 13.40±1.43 14.39±1.42 11.54±1.32 10.32±1.62 12.44±1.82 
3 28.7±1.08 25.76±64 24.45±1.41 23.06±1.22 21.72±1.54 22.25±1.37 18.52±1.30 16.53±1.89 20.21±1.49 
4 42.06±1.31 38.73±1.63 36.39±1.93 33.25±1.82 32.51±1.56 34.71±1.50 25.75±1.53 23.86±1.03 28.45±1.37 
5 57.98±1.83 53.86±1.46 48.47±.1.91 44.44±1.20 40.12±1.87 43.22±1.43 33.21±1.87 34.19±1.07 38.34±1.43 
6 68.10±1.12 62.95±1.66 58.39±1.92 53.52±1.10 49.14±1.53 50.16±1.32 38.31±1.22 41.44±152 44.10±1.26 
8 81.10±1.54 76.65±1.32 73.25±1.77 68.63±1.31 62.78±1.92 63.76±1.39 46.31±1.32 47.40±1.09 51.77±1.93 
12 99.5±1.37 98.85±1.31 97.26±1.63 83.56±1.42 78.43±1.32 76.42±1.20 56.23±1.44 59.54±1.50 61.22±1.45 
16 99.5±1.37 98.85±1.31 97.26±1.63 98.55±1.20 96.98±1.33 95.31±1.90 72.77±1.87 75.89±1.40 70.10±1.59 
20    98.55±1.20 96.98±1.33 95.31±1.90 84.21±1.51 80.19±1.26 78.11±1.30 
24       96.57±1.92 92.32±1.84 90.13±1.63 
All values are in the form of Mean ± SD where n= 3 
 
 
Fig 6: In-vitro Drug Release from Lovastatin Microspheres (All Formulations) 
 
Optimization of LV7 formulation of lovastatin 
microspheres: 
The formulation optimized by implementing 32 factorial 
designs. In this design the polymer concentration and solvent 
ratio using as Independent variable and the levels for 
formulations are Low, Medium and High. The dependent 
variables for studies are Particle size, Buoyancy, Drug 
entrapment and Drug release.  
Table 10 Optimization of Release at 24th Hr 
Regression statistics 
Multiple R              0.9993928 
R Square              0.9987858 
Adjusted R Square             0.996762 
Standard Error                0.6950513 
Observations 9 
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Table 11 Analysis of variance 
ANOVA 
 Degree of 
freedom 
Sum 
Square 
Mean 
Square 
F Significance 
F 
Regression 5 1192.1262 238.42524 493.53559 0.0001435 
Residual 3 1.4492891 0.4830964   
Total 8 1193.5755    
 
 
 
 
 
 
 
 
 
 
 
Fig 7: Contour Plot for Particle Size after Optimization 
 
  
 
 
 
 
 
 
 
 
 
Fig 8: Contour Plot for Buoyancy after Optimization 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 9: Contour Plot for % Drug Entrapment after Optimization 
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Fig 10: Contour Plot for % Drug Release after Optimization 
 
CONCLUSION 
It can be concluded that Floating Microspheres of Lovastatin 
were formed by Solvent Evaporation method .The formulas 
LV7 of Lovastatin Floating Microspheres shows a very good 
drug release profiles and shown better sustained action till 
the end of last hour (24th hrs). It will improve patient 
compliance and increase in bioavailability which give better 
approach to treat hypertensive condition and the 
angiotensin receptor blocking action of Losartan lower the 
long term complications of Hypertension and reduce the risk 
of heart failure, CHF, Myocardial Infarction and also vascular 
damage in blood vessels and kidney. 
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